Left ventricular assist devices (LVADs) are increasingly used to treat advanced heart failure as a bridge to recovery, transplant, or destination therapy, improving patient outcomes and quality of life.1–8 Right heart failure (RHF) affects up to 40% of LVAD patients and is associated with a higher early mortality rate, greater intensive care unit length of stay, higher rates of re-operation for bleeding and renal failure, and a lower bridge-to-transplantation rate.9–12 Approximately 10% of these patients with LVAD need a right ventricular assist device (RVAD), which is difficult to predict before or during LVAD surgery. When an RVAD requirement is identified,12–15 a second open chest procedure is needed for RVAD installation. In most cases, RHF can recover in approximately 2 weeks, and a third open chest procedure is required to remove the RVAD. These two additional major surgical procedures add extra risk to patients with LVAD. Moreover, RVAD installation after LVAD surgery has worse outcomes than planned RVAD installation during LVAD surgery.16
We are developing a convenient and minimally invasive RVAD system based on a percutaneous double-lumen cannula (DLC). This DLC-based percutaneous RVAD (pRVAD) system can be easily placed prophylactically during LVAD implantation and easily removed after RHF resolution without additional open chest surgeries. Our pRVAD system could also be used to treat RHF after heart transplant, myocardial infarction, or cardiotomy.17
The objectives of this study were to design, fabricate, and test the first DLC prototype for its in vivo feasibility/performance as a DLC-based pRVAD system. An optional gas exchanger was also included for concomitant lung function compromise.
Materials and Methods
pRVAD DLC Design and Prototype Fabrication
The pRVAD system consists of a specially designed DLC, a centrifugal pump, and an optional gas exchanger. The critical component of this pRVAD system is the specially designed DLC. This pRVAD DLC is designed to be inserted into the right jugular vein (RJV), advanced through the superior vena cava (SVC), the right atrium (RA), the right ventricle (RV), and ending in the pulmonary artery (PA). Coupled with a pump, the blood is withdrawn from the RA and delivered to the PA, bypassing the RV for right heart assistance (Figure 1).
The pRVAD DLC consists of a main DLC body and a precurved extension infusion cannula (EIC). The pRVAD DLC is constructed of stainless steel wire wound reinforced polyurethane (Figure 2A). The cross-sectional area ratio was 2 (drainage):1 (infusion) in this prototype. The reinforcement coil was made from flat stainless steel wire (0.25 mm thick), which was wound on a smooth mandrel through a wire winding machine. Polyurethane was coated on the stainless steel coil through a proprietary dip molding process, resulting in a flexible yet kink-resistant one-piece (0.7 mm thick) wire. The infusion lumen was an ultrathin polyurethane nondistensible membrane sleeve (0.3 mm thick). The infusion lumen was molded onto the inner sidewall of the DLC outer lumen to form an eccentric configuration. One end of the infusion lumen was connected to the reinforced EIC and the other to the infusion connection tubing. Thermoforming was used to curve the EIC to fit the sharp angle of the RV inflow and outflow tract. A rigid introducer was placed in the infusion lumen to straighten the curved EIC to facilitate percutaneous cannulation (Figure 2).
When the pRVAD DLC is placed correctly, the end openings of the drainage lumen are located in the RA for blood drainage, and the curved EIC ends in the PA for blood delivery. The first DLC prototype was 27 Fr with 0.7 mm outer wall thickness. The infusion lumen was an eccentric thin membrane sleeve (0.3 mm thickness), maximizing cross-sectional area of each DLC lumen for low blood resistance (Figure 1). The cylindrical shape of the membrane sleeve infusion lumen is very stable.18–20 In a traditional DLC, the straight septum is designed to divide a cylinder cannula into two semicylinders as infusion and drainage lumens. When blood flow pumps through a traditional DLC, the pressure difference between the infusion and the drainage lumens makes the septum curve toward the negative pressure side (drainage lumen), making the infusion lumen bigger and the drainage lumen smaller. In our DLC design, this pressure difference would not affect infusion membrane sleeve geometry, and the cross-sectional area of both lumens will be the same at any pressure difference.
pRVAD DLC Prototype Bench Testing
The pRVAD DLC was bench tested for performance (flow pressure). The bench test circuit included a CentriMag blood pump (Thoratec Corporation, Pleasanton, CA) connected to the pRVAD DLC by 20 cm of Tygon tubing (Medtronic, Minneapolis, MN) (3/8 in). The DLC was hooked to a reservoir. This circuit and reservoir were primed with 37% glycerin to mimic human blood viscosity. Two pressure sensors (Transpac, ICU Medical, San Clemente, CA) were placed in inlet and outlet connectors of the pRVAD DLC for drainage and infusion pressures. The flow sensor (9XL, Transonic Inc., Ithaca, NY) was placed on the circuit tubing for pump flow measurement. The data acquisition system (cDAQ9172, National Instruments, Austin, TX) with a pressure module (NI 9237), a flow module (NI 9215), and a flow meter (HT110, Transonic Inc.) was used to monitor/record pressure and circuit flow. The pump was adjusted to target flow at 1, 2, 3, 4, and 4.5 L/min, with the corresponding drainage and infusion pressures recorded.
pRVAD DLC Prototype Animal Testing
All animal studies were approved by the University of Kentucky Institutional Animal Care and Use Committee and were conducted in accordance with the Principles of Laboratory Animal Care (National Society of Medical Research) and the “Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 85-23, revised 1996).” The pRVAD system included the DLC, the CentriMag blood pump, and an optional gas exchanger (Affinity, Medtronics, Minneapolis, MN). The blood pump and gas exchanger were connected and primed with Ringer’s solution.
Animal anesthesia, instrumentation, and surgical procedure.
Six crossbred adult sheep (40–60 kg) were used to test the pRVAD system. After anesthesia induction with ketamine and diazepam, all sheep were intubated and connected to the anesthesia machine (Narkomed 2B, Drager, Telford, PA). Anesthesia was maintained with 1–3% isoflurane, titrating a normal range of heart rate and arterial blood pressure (ABP). Arterial/venous catheters (BD Medical Inc., Sandy, UT) were placed into right femoral artery/vein for pressure monitoring and fluid administration. A right lateral thoracotomy was performed through the fifth intercostal space. The pericardium was opened to expose the SVC and the RA. A rigid introducer was placed inside the DLC infusion lumen, straightening the curved EIC. A bolus of heparin (200 unit/kg) was administered intravenously for systemic heparinization, maintaining an activated clotting time of 300–400 sec. A 2 cm cut down was made on the right neck to expose the RJV for cannulation. A veinotomy was made on the RJV. The DLC along with the rigid introducer was inserted through the veinotomy into the RJV-SVC. As the DLC tip reached the RA (identified by finger palpation), the introducer was held and no longer moved forward while the DLC was continuously advanced. Losing the support of the rigid introducer, the EIC tip curved to cross the tricuspid valve to the RV. The EIC was progressively moved over the introducer tip, increasing curvature. This curved EIC crossed the RV outflow tract and the pulmonary valve to end in the PA. The DLC drainage lumen openings at the end of the main DLC body were located in the RA, and the end of the EIC was located in the PA. After removal of the introducer, the DLC was connected to a primed CentriMag pump—Affinity oxygenator circuit. Venous blood was withdrawn from the RA, went through the oxygenator for gas exchange, and was pumped into the PA, bypassing the RV for right heart and pulmonary assistance. The RA is a low-pressure flexible chamber. Excessive pumping speed will cause negative RA pressure and RA collapse. The collapsed RA wall will obstruct the drainage opening and dramatically decrease RVAD flow. Therefore, maximal pumping blood flow was obtained by adjusting the pump speed until central venous pressure (CVP) was >1 mm Hg to prevent RA collapse. This maximal pumping flow was maintained for 2 hours. The sweep gas (100% oxygen at 5 L/min) was connected to the gas exchanger.
Monitoring and data collection.
Arterial blood pressure and CVP were continuously monitored by a IntelliVue MP50 patient monitor (Philips Healthcare, Andover, MA). The maximal pump flow was recorded every 45 minutes. Outlet sweep gas was monitored for CO2 concentration by a Philips Capnography Extension. The pre and post gas exchanger blood was sampled for blood gas analysis. The CO2 removal was calculated by multiplying the sweep gas flow rate and the outlet CO2 concentration. The O2 transfer was calculated according to the following equation21:
where ΔO2 sat and ΔPO2 were the change in blood O2 saturation and oxygen pressure across the gas exchange device, respectively.
The pRVAD DLC prototype was successfully made. The main DLC body was 27 Fr, and the EIC was 21 Fr. In our bench testing with 37% glycerin solution, 4 L/min pumped through the DLC against a 217 mm Hg pressure in the infusion lumen and a −105 mm Hg pressure in the drainage lumen (Figure 3). When the pump was turned up to 5.0 L/min flow, the DLC remained intact without deforming.
In the animal testing, the pRVAD DLC was inserted into the RJV and deployed into the RA with the help of manual guide over the RA and RV in all six adult sheep. Maximal pumping flow was maintained for 2 hours. In the first three sheep, the maximal average RVAD pumping flow was 1.8–2.6 L/min because the DLC was advanced too far with the drainage opening sucked against the RA side wall. In the last three sheep with a well-positioned DLC, the average flow was 3.8–4.4 L/min (Table 1). Tachycardia arrhythmia was found in two sheep.
All venous blood was completely arterialized through the gas exchanger with the post gas exchanger O2 saturation at 100% and PCO2 ≤40 mm Hg. The O2 transfers were 68, 76, and 85 ml/min in the first three sheep, respectively, and 127, 174, and 206 ml/min in the fourth, fifth, and sixth sheep, respectively. The CO2 removal was up to 246 ml/min (Table 1).
During autopsy, all six pRVAD DLCs fit the contour of the RA-RV-PA, with the drainage lumen openings in the RA and the EIC end in the main PA (Figure 4). No damage was observed in the RA, RV, PA, tricuspid valve, and pulmonary valve. No thrombosis was found in the RA, RV, PA, and inside or outside the DLC. The DLC was easily removed from the sheep.
Our preliminary in vivo study shows the feasible percutaneous insertion/placement, good performance, and easy removal of our pRVAD DLC prototype. This DLC-based pRVAD system can pump more than 4 L/min blood flow for RV and lung support in healthy sheep weighing 50 kg. This technology could be prophylactically placed during LVAD surgery to support post-LVAD RHF, eliminating two additional open chest surgeries for RVAD installation and removal.
An RVAD is needed in 10% of patients with LVAD for RHF complication. This RVAD requirement is usually identified after LVAD surgery.12–15 Although several compact pumps have been specifically developed for RVAD application,10,22–24 they all require open chest surgeries to connect and remove from the pulmonary circulation. A pRVAD system would be advantageous over a traditional RVAD system to avoid two open chest surgeries and associated trauma.
Percutaneous left ventricular (LV) support (intra-aortic blood pump (IABP) and Impella Pump) has already been developed for temporary LV assist through percutaneous femoral artery insertion. Compared with femoral artery–aorta blood path for percutaneous LVAD (pLVAD), the RVAD is much more amenable for percutaneous access because the RJV–SVC–RV is a very low-pressure blood path with very limited potential bleeding complication. The large RJV in the adult can accommodate up to a 31 Fr cannula for a pRVAD system, allowing sufficient blood flow for RV support.
The existing pRVAD with two separate cannulations is an off-label application of the TandemHeart pLVAD (CardiacAssist Inc., Pittsburgh, PA). The TandemHeart transseptal cannula, originally designed as a LVAD left atrium drainage cannula, is used as a PA infusion cannula in RVAD application. An additional cannula is required for drainage from the vena cava. Extracorporeal centrifugal pumps such as the TandemHeart Pump and the CentriMag (Thoratec Corporation) are used to withdraw the blood from the vena cava and to infuse blood into the PA. This technology has been applied in 101 patients with refractory RHF, proving the feasibility of a pRVAD.25 The CentriMag was also used in this percutaneous configuration in eight patients for short-term RV support as a bridge to recovery and biventricular assist device (BiVAD).17,26 However, this technology requires two separate cannulations, long connection tubing, and complicated circuit, preventing patient mobility.
The Impella RP (Abiomed, Danvers, MA) is a catheter-based microaxial pump designed for up to 4.8 L/min pumping flow and up to 2 weeks of support. Successful application of the Impella RP in four patients with RHF has been reported.27–29 The results of the recently finished Canadian/European clinical trial was presented at the 2012 American College of Cardiology meeting,30 but the data have not been formally published yet. Currently, a US clinical trial is ongoing to test the Impella RP device.28 However, this device is placed through the femoral vein, which greatly limits patient mobility.
Our pRVAD DLC specifically addresses the problems of long circuit, high circuit blood resistance, and lack of patient mobility. This DLC, through a single RJV cannulation, leads to a pRVAD system with very short circuit, less resistance, and good potential for patient ambulation. Our previous patented extracorporeal membrane oxygenation (ECMO) DLC (Avalon Elite, Rancho Dominguez, CA) has successfully proved this concept.21 The Avalon Elite DLC-ECMO circuit is much shorter with much lower resistance than the ECMO circuit with two single-lumen cannulas. The Avalon Elite DLC spares the femoral vein, enabling patient ambulation.
In DLC design, too much negative pressure in the drainage lumen is believed to be unsafe and should be avoided. Usually, one-third of the pressure gradient is distributed to the drainage lumen and two-third to the infusion lumen. To achieve this pressure gradient distribution, the lumen cross-sectional area ratio is set at 2 (drainage):1 (infusion). Therefore, the cross- sectional area ratio was 2 (drainage):1 (infusion) in this prototype, which originated from Avalon Elite. However, in this pRVAD DLC, the length of the drainage lumen is much shorter than the infusion lumen, and the 2:1 ratio is not suitable. Therefore, a computational fluid dynamics investigation is needed to optimize the geometry of the cannula to target a 2 (drainage):1 (infusion) pressure gradient.
The challenge of developing a percutaneous DLC for a RVAD system is the positioning of the infusion cannula into the PA through the sharp angle between the RV inflow and the RV outflow tracts. We designed the pRVAD DLC with a curved EIC to fit this sharp angle. The rigid introducer inside the DLC infusion lumen straightens the curved EIC for easy percutaneous insertion from the RJV. When the introducer tip enters the RA, the DLC is continuously advanced, whereas the introducer is held still. Then the EIC loses the support of the rigid introducer, curving into the RV and PA. This study demonstrated the feasibility of percutaneous DLC placement in adult sheep. The RVAD performance was compromised in the first three sheep because deep cannula placement caused drainage opening suction against RA wall. Although this problem was resolved by less advancement of the pRVAD DLC into the RA, we will redesign the pRVAD DLC to completely resolve this position-induced drainage obstruction. We will also embed a catheter inside the introducer to aide pRVAD DLC placement.
Lung function compromise may coexist with RHF because of cardiogenic lung edema, inflammatory reaction to cardiopulmonary bypass, or lung infection. Our DLC-based pRVAD system has the flexibility to connect an optional gas exchanger to provide total respiratory support for concurrent compromised lung function.
Although our current pRVAD DLC placement through open chest surgery is justified by the proposed cannula placement during open chest LVAD implantation surgery, we did not test percutaneous DLC placement because of the lack of image guidance equipment. Another limitation of this study is that cardiac output was not measured. In our pRVAD system, the blood was withdrawn from the RA outside the body and delivered back to the PA. This extracorporeal circuit results in blood heat loss. Therefore, the thermodilution method through a Swan–Ganz catheter is no longer suitable for cardiac output measurement. However, we plan to place an ultrasound flow sensor in aortic root to measure cardiac output in future animal studies. In this feasibility study, the pRVAD was evaluated only for 2 hours. Long-term studies are needed to fully evaluate the performance of the cannula. Also, the potential for valve damage could not be evaluated in this short in vivo study. A long-term animal study is required to assess whether there is any potential for valve damage. Thrombosis in the RJV after use of the Avalon Elite has been reported.31 Although this thrombosis may be removed by a minor surgery during DLC withdrawal,31 this potential drawback may dampen enthusiasm for the pRVAD DLC because the RJV is a frequent site for endomyocardial biopsies after heart transplant.
Our DLC-based pRVAD system is feasible for percutaneous right heart assistance through a single-site RJV cannulation. This pRVAD DLC can be easily placed prophylactically during LVAD implantation and removed as needed, eliminating two open chest procedures.
1. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WDResource Utilization Among Congestive Heart Failure (REACH) Study. . Confirmation of a heart failure epidemic: Findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60–69
2. Ramani GV, Uber PA, Mehra MR. Chronic heart failure: Contemporary diagnosis and management. Mayo Clin Proc. 2010;85:180–195
3. Krishnamani R, DeNofrio D, Konstam MA. Emerging ventricular assist devices for long-term cardiac support. Nat Rev Cardiol. 2010;7:71–76
4. Rogers JG, Aaronson KD, Boyle AJ, et al.HeartMate II Investigators. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. 2010;55:1826–1834
5. John R, Lee S, Eckman P, Liao K. Right ventricular failure—A continuing problem in patients with left ventricular assist device support. J Cardiovasc Transl Res. 2010;3:604–611
6. Slaughter MS, Rogers JG, Milano CA, et al.HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–2251
7. Long JW, Kfoury AG, Slaughter MS, et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: Improved outcomes since the REMATCH study. Congest Heart Fail. 2005;11:133–138
8. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: Implications for patient selection. Circulation. 2007;116:497–505
9. Fitzpatrick JR III, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant. 2008;27:1286–1292
10. Furukawa K, Motomura T, Nosé Y. Right ventricular failure after left ventricular assist device implantation: The need for an implantable right ventricular assist device. Artif Organs. 2005;29:369–377
11. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol. 2008;51:2163–2172
12. Dang NC, Topkara VK, Mercando M, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant. 2006;25:1–6
13. Fukamachi K, McCarthy PM, Smedira NG, Vargo RL, Starling RC, Young JB. Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann Thorac Surg. 1999;68:2181–2184
14. Kavarana MN, Pessin-Minsley MS, Urtecho J, et al. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: A continuing problem. Ann Thorac Surg. 2002;73:745–750
15. Ochiai Y, McCarthy PM, Smedira NG, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: Analysis of 245 patients. Circulation. 2002;106(12 suppl 1):I198–I202
16. Fitzpatrick JR III, Frederick JR, Hiesinger W, et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg. 2009;137:971–977
17. Hsu PL, Parker J, Egger C, Autschbach R, Schmitz-Rode T, Steinseifer U. Mechanical circulatory support for right heart failure: Current technology and future outlook. Artif Organs. 2012;36:332–347
18. Wang D, Zhou X, Liu X, Sidor B, Lynch J, Zwischenberger JB. Wang-Zwische double lumen cannula—Toward a percutaneous and ambulatory paracorporeal artificial lung. ASAIO J. 2008;54:606–611
19. Bermudez CA, Rocha RV, Sappington PL, Toyoda Y, Murray HN, Boujoukos AJ. Initial experience with single cannulation for venovenous extracorporeal oxygenation in adults. Ann Thorac Surg. 2010;90:991–995
20. Garcia JP, Iacono A, Kon ZN, Griffith BP. Ambulatory extracorporeal membrane oxygenation: A new approach for bridge-to-lung transplantation. J Thorac Cardiovasc Surg. 2010;139:e137–e139
21. Zhou X, Wang D, Sumpter R, Pattison G, Ballard-Croft C, Zwischenberger JB. Long-term support with an ambulatory percutaneous paracorporeal artificial lung. J Heart Lung Transplant. 2012;31:648–654
22. Furukawa K, Motomura T, Hata A, et al. Development of implantable right ventricular assist device. ASAIO J. 2004;50:543–549
23. Fukamachi K, Saeed D, Massiello AL, et al. Development of DexAide right ventricular assist device: Update II. ASAIO J. 2008;54:589–593
24. Fukamachi K, Ootaki Y, Horvath DJ, et al. Progress in the development of the DexAide right ventricular assist device. ASAIO J. 2006;52:630–633
25. Kapur NK, Paruchuri V, Korabathina R, et al. Effects of a percutaneous mechanical circulatory support device for medically refractory right ventricular failure. J Heart Lung Transplant. 2011;30:1360–1367
26. Takayama H, Naka Y, Kodali SK, et al. A novel approach to percutaneous right-ventricular mechanical support. Eur J Cardiothorac Surg. 2012;41:423–426
27. Goldstein JA, Kern MJ. Percutaneous mechanical support for the failing right heart. Cardiol Clin. 2012;30:303–310
28. Cheung AW, White CW, Davis MK, Freed DH. Short-term mechanical circulatory support for recovery from acute right ventricular failure: Clinical outcomes. J Heart Lung Transplant. 2014;33:794–799
29. Margey R, Chamakura S, Siddiqi S, et al. First experience with implantation of a percutaneous right ventricular Impella right side percutaneous support device as a bridge to recovery in acute right ventricular infarction complicated by cardiogenic shock in the United States. Circ Cardiovasc Interv. 2013;6:e37–e38
30. Cheung A, Freed D, Hunziker P, Leprince P. First clinical evaluation of a novel percutaneous right ventricular assist device: The Impella RP. J Amer Coll Cardiol. 2012;60:B106–B107
31. Zhou X, Liang XM, Zhao G, Su Y, Wang Y. A new computational fluid dynamics method for in-depth investigation of flow dynamics in roller pump systems. Artif Organs. 2014;38:E106–E117